Blue Fin Capital Inc. Has $2.45 Million Position in Merck & Co., Inc. (NYSE:MRK)

Blue Fin Capital Inc. raised its position in Merck & Co., Inc. (NYSE:MRKGet Rating) by 0.5% during the 1st quarter, according to its most recent filing with the SEC. The institutional investor owned 29,844 shares of the company’s stock after acquiring an additional 141 shares during the period. Blue Fin Capital Inc.’s holdings in Merck & Co., Inc. were worth $2,448,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. BlackRock Inc. lifted its position in Merck & Co., Inc. by 5.5% during the 4th quarter. BlackRock Inc. now owns 198,224,263 shares of the company’s stock worth $15,191,909,000 after buying an additional 10,326,974 shares in the last quarter. State Street Corp increased its position in shares of Merck & Co., Inc. by 2.7% in the fourth quarter. State Street Corp now owns 118,668,673 shares of the company’s stock valued at $9,174,491,000 after acquiring an additional 3,132,078 shares during the last quarter. Geode Capital Management LLC raised its holdings in Merck & Co., Inc. by 12.7% during the fourth quarter. Geode Capital Management LLC now owns 48,153,283 shares of the company’s stock worth $3,682,009,000 after acquiring an additional 5,409,154 shares in the last quarter. Charles Schwab Investment Management Inc. raised its holdings in Merck & Co., Inc. by 5.5% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 29,002,620 shares of the company’s stock worth $2,222,762,000 after acquiring an additional 1,500,754 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA grew its stake in Merck & Co., Inc. by 13.7% in the fourth quarter. Massachusetts Financial Services Co. MA now owns 28,981,674 shares of the company’s stock valued at $2,221,156,000 after purchasing an additional 3,484,786 shares in the last quarter. Institutional investors own 72.88% of the company’s stock.

MRK has been the subject of several recent analyst reports. SVB Leerink reissued an “outperform” rating and issued a $102.00 price objective on shares of Merck & Co., Inc. in a report on Monday, June 6th. Morgan Stanley cut their price target on shares of Merck & Co., Inc. from $82.00 to $80.00 and set an “equal weight” rating for the company in a research note on Wednesday, April 6th. StockNews.com initiated coverage on shares of Merck & Co., Inc. in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock. Barclays raised their target price on shares of Merck & Co., Inc. from $94.00 to $97.00 and gave the company an “overweight” rating in a research note on Tuesday, April 12th. Finally, Mizuho began coverage on Merck & Co., Inc. in a research report on Friday, April 1st. They set a “buy” rating and a $100.00 price target on the stock. Seven equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $91.60.

Shares of NYSE:MRK opened at $89.16 on Thursday. Merck & Co., Inc. has a 12-month low of $70.89 and a 12-month high of $94.92. The company’s 50 day moving average price is $88.75 and its two-hundred day moving average price is $82.17. The firm has a market cap of $225.47 billion, a PE ratio of 15.95, a PEG ratio of 1.19 and a beta of 0.36. The company has a quick ratio of 1.14, a current ratio of 1.40 and a debt-to-equity ratio of 0.75.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its quarterly earnings results on Thursday, April 28th. The company reported $2.14 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.81 by $0.33. The business had revenue of $15.90 billion for the quarter, compared to the consensus estimate of $14.64 billion. Merck & Co., Inc. had a return on equity of 47.86% and a net margin of 26.27%. The firm’s quarterly revenue was up 31.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.40 earnings per share. On average, research analysts expect that Merck & Co., Inc. will post 7.32 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, July 8th. Investors of record on Wednesday, June 15th will be paid a $0.69 dividend. This represents a $2.76 dividend on an annualized basis and a yield of 3.10%. The ex-dividend date is Tuesday, June 14th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 49.37%.

Merck & Co., Inc. Company Profile (Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

See Also

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.